protein

Recombinant Paraoxonase 1 (PON1)

MBS2009327

0.01 mg

150 USD

Recombinant Protein

Recombinant Paraoxonase 1 (PON1)

[Paraoxonase 1 (PON1)]

[serum paraoxonase/arylesterase 1; Serum paraoxonase/arylesterase 1; serum paraoxonase/arylesterase 1; PON 1; A-esterase 1; aromatic esterase 1; serum aryldialkylphosphatase 1; paraoxonase 1; Aromatic esterase 1; A-esterase 1; Serum aryldialkylphosphatase 1]

[PON1]

[Pon1; Pon1; Pon; PON 1]

PON1_RAT

E.coli

Rat

>92%

20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% sarcosyl, 5%Trehalose and Proclin300.

200ug/mL

Storage : Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months. Stability Test : The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 degree C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

SDS-PAGE, WB, ELISA, IP, CoIP, Purification, Amine Reactive Labeling. (May be suitable for use in other assays to be determined by the end user.)

Sequence Information

SDS-Page

Source: Prokaryotic expression. Residues: Ala2~Phe186. Tags: N-terminal His-Tag. Tissue Specificity: Liver, Kidney. Subcellular Location: Secreted, extracellular space. Traits: Freeze-dried powder.

Predicted isoelectric point: 5.5. Predicted Molecular Mass: 21.7kDa. Accurate Molecular Mass: 21kDa as determined by SDS-PAGE reducing conditions. Usage: Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

54292130

NP_114466.1

NM_032077.1

P55159

Phase I, Non P450 Pathway (219787)

may protect LDL and HDL from oxidation and provide protection against atherosclerosis [RGD, Feb 2006]

PON1: Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation. Genetic variation in PON1 is associated with susceptibility to microvascular complications of diabetes type 5 (MVCD5). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new- onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Homozygosity for the Leu-54 allele is strongly associated with the development of retinal disease in diabetic patients. Belongs to the paraoxonase family. Protein type: Secreted; Hydrolase; Motility/polarity/chemotaxis; Lipid-binding; EC 3.1.1.2; EC 3.1.1.81; EC 3.1.8.1; Secreted, signal peptide; Phosphatase (non-protein). Cellular Component: extracellular space; intracellular membrane-bound organelle. Molecular Function: protein homodimerization activity; arylesterase activity; phospholipid binding; calcium ion binding; aryldialkylphosphatase activity. Biological Process: response to nutrient levels; cholesterol metabolic process; dephosphorylation; response to toxin; organophosphate catabolic process; positive regulation of transporter activity; carboxylic acid catabolic process; lipid metabolic process; positive regulation of binding; aromatic compound catabolic process; phosphatidylcholine metabolic process

0.01 mg

150 USD

0.05 mg

295

0.1 mg

460

0.2 mg

570

0.5 mg

1105

1 mg

1645